罗氏(ADR) 2025年度报告

Patient advocate Vanessa Carter battled infection and antimicrobialresistance for three years. “Antibiotics are a precious resource.We need to protect them and keep finding new ones.” When the medicine stops working She survived antibiotic resistance. Now she helps others understand its impact. A devastating car crash nearly killed Vanessa Cartertwo decades ago, shattering her bones and severelyinjuring her face. What followed was an even greaterbattle, one that couldn’t be seen. For Vanessa, recovery came through persistence.She sought help from a transplant surgeon inBoston who created a plan to remove the infectionand complete her reconstruction in as few surgeriesas possible. Working with South African doctorswho carried out the procedures, she underwenttwo operations and a final course of last-resortantibiotics. Her long fight to rebuild her facefinally ended. Vanessa, a mother of two now living in the UK,underwent multiple surgeries to rebuild her faceand fight a stubborn infection that no antibioticseemed able to stop. “Every single day waking upto a recurring infection was frightening,” she says.“I kept looking in the mirror and seeing this infectioneating away at my face and wondering, am I goingto have a face in the morning? How much furtherdamage is it going to do?” “We often think antibiotics can cure anything, butAMR can happen to anybody. You get so used toantibiotics working and then one day they just don’t,”she says. “I told myself if I get out of this alive, I amgoing to make a difference for others.” She often thinks of the 2004 collision inJohannesburg, South Africa, when another driverveered into her lane. She lost her right eye and wentthrough dozens of surgeries to rebuild her face andremove the infection. Each time, it returned. “Theywere prescribing the same type of antibiotic overand over, and it wasn’t working,” Vanessa recalls. From survivor to advocate Driven by her experience, Vanessa speakspublicly on the need for responsible antibiotic useand the importance of early, accurate diagnosisto stop infection. She collaborates with healthorganisations and researchers to help othersunderstand the patient impact of AMR. Her storyis a powerful reminder that behind every statisticthere are people fighting to live and that awarenesscan save lives. An invisible enemy The bacteria inside her wounds had changed.They had learnt to survive. The infection –called methicillin-resistantStaphylococcusaureus(MRSA) infection – no longer responded tomedicines that once worked. “A surgeon told me ifthe infection hit my bloodstream, I could die. Therewere nights I lay awake wondering if it would kill me.I just wanted to know why it kept coming back.” Through her non-profit organisation, The AMRNarrative, Vanessa educates the public andhealthcare workers on reducing AMR, emphasisingfoundational steps like hand hygiene and correctantibiotic use. The answer, she later learnt, was antimicrobialresistance, or AMR. It happens when microbes,like bacteria, adapt so that treatments stop beingeffective. It is a growing global threat that putsmillions of lives at risk. A study in ‘The Lancet’estimates that more than 39 million people coulddie from drug-resistant infections between 2025and 2050.1 At the same time, researchers at Roche are aimingto develop a new class of antibiotics as part of aglobal effort to fight antimicrobial resistance andhopefully protect future generations. “Antibiotics are a precious resource,” Vanessa says.“They save so many lives, and we need to protectthem and keep finding new ones.” Inside the race to stop drug-resistant infections The future of modern medicine depends on new antibiotics. Meet Roche scientistson a personal mission to deliver the next generation of these life-saving medicines. It’s a threat that rarely makes headlines but killsmillions. Antimicrobial resistance, or AMR, occurswhen germs evolve to defeat the drugs meant tokill them. It’s a silent pandemic linked to nearlyfive million deaths each year.¹ The challenge is an enemy that has perfectedsurvival. “Bacteria have been on the planet forover a billion years,” Ken says. “They are expertsat evolving. We need to stay one step ahead.” That’s why simply making more of the sameantibiotics won’t work. “Bacteria are very clever,”explains Roche scientist Séverine Louvel, whohas spent a decade at Roche researching newantibiotics. If a new drug is too similar to anold one, “they will know exactly what to do andbecome resistant quickly. We need to developradically new antibiotics.” For Roche scientists, this isn’t a distant problem. It’sa daily battle to protect modern medicine. “Anybodycould be vulnerable – when they break a leg, havea car accident or undergo surgery,” says Rochescientist Emmanuelle Cottreel. She describes aworld where common infections could once againbecome deadly. Séverine is driven by this mission. She recalls anacademic clinical trial expert who was excitedto test her team’s new drug